BioChem Pharma begins Phase III with Troxatyl

BioChem Pharma (BCHE; TSE:BCH) began a U.S. Phase III study of its Troxatyl troxacitabine dioxolane nucleoside analog in up to 100 patients with previously untreated poor prognosis acute myelogenous l...